Comparative dosimetry study of PARaDIM and RT-PHITS with ICRP publication 128: calculation of organ doses from 18F-FDG radiopharmaceutical
Abstract
This study evaluates organ doses from ¹⁸F-FDG whole-body PET-CT using the phantom-based software PARaDIM and patient image-based software RT-PHITS and compares with reference data from ICRP Publication 128. Absorbed dose coefficients (mGy/MBq) were calculated using ICRP Publication 145 mesh-type phantoms in PARaDIM and 20 patient datasets (10 male, 10 female) from 'The Cancer Imaging Archives' website in RT-PHITS. Organs were segmented in 3D Slicer, and dose coefficients were derived after physical decay correction of the resultant dose rates (mGy/s). The patient cohort (n = 20; 10 males, 10 females) had an average age of 52.1 years, height of 172.1 cm, weight of 76.65 kg, and total administered activity of 306.55 MBq. Absorbed dose coefficients from PARaDIM and RT-PHITS ranged from 0.01 to 0.07 mGy/MBq. RT-PHITS showed acceptable agreement with ICRP 128 and PARaDIM for most organs, except for the urinary bladder and heart wall. Standard deviations (SD) for RT-PHITS urinary bladder doses were 0.04 relative to ICRP 128 and 0.12 relative to PARaDIM; heart wall SDs were 0.016 and 0.014, respectively. Overall, RT-PHITS organ doses yielded an average SD of 0.0073, with the highest deviation in the heart wall. The results indicate that anatomical differences lead to measurable variations between the generalized and individualized dosimetry methodologies. Because a consistent physical decay model of 18F was used, these variations primarily reflect structural and geometric factors.…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 20 participants or records.
Read the paper
Related studies
- Quantum dots: synthesis, bioapplications, and toxicity
- A Guide to In Silico Drug Design
- Quantum Computing for Healthcare: A Review
- Automated in Silico Design of Homogeneous Catalysts
- Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using in silico Structure-Based Combinatorial Library Design Approach
- In silico structural elucidation of RNA-dependent RNA polymerase towards the identification of potential Crimean-Congo Hemorrhagic Fever Virus inhibitors
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.